Consistently, treatment of GBM patients with the angiogenesis inhibiting anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is linked to enhanced invasion and multifocal tumour recurrence7, 8, 9, which is associated with aggravated mental decline. This evidence concerns the gene VEGFA and glioblastoma.